Unpacking the true financial footprint of private health coverage. A detailed look at the systemic factors eroding expected ...

State and federal Oklahoma lawmakers say they plan to prioritize enforcement actions on pharmacy benefit managers, the ...

Median net sales for the 19 drugs in 2022 were $1.97 billion (range, $988 million-$8.36 billion). The drugs with the highest net sales were lenalidomide (Revlimid; $8.36 billion), ...

Nearly 20 expensive medications will escape Medicare price negotiations under the 2025 budget law, costing patients and ...

Direct-to-consumer sales of medications often mean lower prices and more convenience for patients.

Eli Lilly and Novo Nordisk have agreed to sell their weight loss drugs, Wegovy and Zepbound, through the new TrumpRx ...

Oregon Health & Science University leaders say a federal drug discount pilot set to begin next year could create a ...

Premiums and prescription prices are rising for North Carolina Medicare enrollees in 2026 as plan choices narrow and benefits shift.

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1,350 a month. Under the ...

Trump’s GLP-1 price deal slashes costs and expands selective Medicare coverage—threatening telehealth startups and sparking a ...

A supply fee for drugs subject to Medicare Part D price negotiations is being touted as “essential” to the sustainability of long-term care pharmacies that serve assisted living communities and ...

With pricing pressures climbing, Pfizer, Eli Lilly and other major drugmakers are looking to sell their products directly to ...